Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$536.87 USD
+5.01 (0.94%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $536.96 +0.09 (0.02%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$536.87 USD
+5.01 (0.94%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $536.96 +0.09 (0.02%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Solid Consumables Drive Illumina's (ILMN) Q1 Earnings?
by Zacks Equity Research
Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.
Top Ranked Momentum Stocks to Buy for April 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 16th
Can Medical Devices Strength Drive Abbott (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) expects high single-digit growth in Medical Devices' sales in first-quarter 2019 and continued double-digit growth in certain sub-segments.
Will Abbott's (ABT) Steady Overall Growth Aid Q1 Earnings?
by Zacks Equity Research
At the end of 2018, Abbott (ABT) posts some encouraging data, buoying investors' optimism on its Diabetes Care segment.
The Zacks Analyst Blog Highlights: Mastercard, Honeywell, Thermo Fisher, Cigna and Norfolk Southern
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Honeywell, Thermo Fisher, Cigna and Norfolk Southern
Zacks.com featured expert Kevin Matras highlights: SS&C Technologies, Thermo Fisher Scientific, Columbia Sportswear, Heidrick & Struggles International and Anthem
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: SS &C Technologies, Thermo Fisher Scientific, Columbia Sportswear, Heidrick & Struggles International and Anthem
Thermo Fisher (TMO) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Top-Ranked Dividend Stocks That Ensure Solid Growth
by Sweta Killa
Given a dovish Fed and bouts of market volatility, investors are in search of steady income with some aspect of growth.
5 Top-Ranked Dividend Stocks That Ensure Solid Growth
by Sweta Killa
Given a dovish Fed and bouts of market volatility, investors are in search of steady income with some aspect of growth.
Top Analyst Reports for Mastercard, Honeywell & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Honeywell (HON) and Thermo Fisher (TMO).
Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip
by Zacks Equity Research
On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.
The Zacks Analyst Blog Highlights: Amazon, Berkshire Hathaway, Thermo Fisher, Square and Public Service
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Berkshire Hathaway, Thermo Fisher, Square and Public Service
Semtech (SMTC) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Semtech's (SMTC) differentiated growth drivers and diversification strategy are likely to drive fiscal fourth-quarter results. However, exposure to seasonality and competition remain concerns.
Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
Roper (ROP) Sells Scientific Imaging Businesses to Teledyne
by Zacks Equity Research
The divestment of Roper's (ROP) Scientific Imaging businesses is in sync with its inorganic growth strategy.
The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer
Top Analyst Reports for Boeing, Thermo Fisher & Anthem
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Thermo Fisher (TMO) and Anthem (ANTM).
Thermo Fisher (TMO) Beats on Earnings and Revenues in Q4
by Zacks Equity Research
Thermo Fisher (TMO) gains on growth in all business segments in Q4.
Thermo Fisher Scientific (TMO) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.88% and 4.32%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher (TMO) Down on Business Divestment Declaration
by Zacks Equity Research
Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.
Will Overall Growth Aid Thermo Fisher's (TMO) Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) rides high on a steadily strong analytical instrument business, flaunting robust global demand.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.